Comparative Pharmacology
Head-to-head clinical analysis: EDARBI versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBI versus TRIVARIS.
EDARBI vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination